Phase 3 N=167 Maintenance Intravenous Fluids in Children
Hyponatremia
Primary: Incidence of Hyponatremia (Defined as Serum Sodium Less Than 130 mmol/L) — 1; 2; 8 participants — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=40 Regenafil Versus Demineralized Freeze Dried Bone Allograft (DFDBA) for Periodontal Defects
Periodontal Diseases
Primary: Change in Probing Depth — 2.7; 2.4 mm — p=>.05
Phase 3 N=192 Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
Crohn's Disease
Primary: Percent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 26 — 28.4; 38.7 percent of participants…
Phase 3 N=267 Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity
Influenza
Primary: Seroprotection Rate Infants (6-11 Months)-A/Brisbane/59/07(H1N1) — 41; 34 participants
Phase 3 N=68 Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients
Friedreich's Ataxia
Primary: Change in ICARS — 1.1 units on a scale
Phase 3 N=425 Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions
Breast Cancer With Bone Metastasis
Primary: Annual Overall Skeletal Morbidity Rate (SMR) — 0.26; 0.22 Number of Skeletal Events per Year
Phase 3 N=857 Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline at Week 24 — 0.13; -0.64; -1.07; -0.45 Percent — p=<0.0001
Phase 3 N=83 Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients
Vascular Diseases
Primary: Number of Vessel Segments Visualized With Diagnostic Quality — 8.10; 8.33; 8.03; 8.33 vessel segments
Phase 3 N=97 DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
Multiple Myeloma
Primary: Transplant With DT PACE-Melphalan Regimen of Chemotherapy vs. Transplant With Melphalan Alone.
Phase 3 N=165 SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
Brain Metastases
Primary: Number of Lesions Detected by Blinded Readers (BR) and Investigator — 6.28; 6.92; 6.87; 6.36 lesions
Phase 3 N=628 Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
Asthma
Primary: Rate of Clinically Significant Asthma Exacerbations Per Patient in the 24-week Fixed-dose Steroid Treatment Period — 0.45; 0.64 Exacerbations per patient per 24-weeks
Phase 3 N=960 A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
Carcinoma, Non-Small Cell Lung
Primary: Overall Survival (OS) — 9.0; 8.5 Months — p=0.1933
Phase 3 N=223 A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters
Dysfunctional Hemodialysis Catheters
Primary: Percentage of Participants Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1 — 34.1 Percentage of participants
Phase 3 N=561 Japanese P III vs Voglibose and Placebo
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c at Week 12 — 0.63; -0.24; -0.25 Percent — p=<0.0001
Phase 3 N=196 Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis
Sepsis
Primary: Amount of Study Drug Required to Achieve Initial Hemodynamic Stabilization — 1379; 1709 Milliliter — p=0.0185